Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications in cancer management. While its role in guiding precision medicine in certain tumors via noninvasive detection of susceptibility and resistance alterations is now well established, recent evidence has pointed to more generalizable use in treatment monitoring. Quantitative changes in ctDNA levels over time (i.e., ctDNA kinetics) have shown potential as an early indicator of therapeutic efficacy and could enable treatment adaptation. However, ctDNA kinetics are complex and heterogeneous, affected by tumor biology, host physiology, and treatment factors. This review outlines the current preclinical and clinical knowledge of ctDNA kinetics in cancer and how early on-treatment changes in ctDNA levels could be applied in clinical research to collect evidence to support implementation in daily practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791609 | PMC |
| http://dx.doi.org/10.1126/sciadv.abi8618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.
Clin Colorectal Cancer
December 2024
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Faculty of Technology, Natural Sciences and Maritime Sciences, University of South-Eastern Norway, Bø in Telemark, Norway.
Article Synopsis
- Early identification of patients with metastatic colorectal cancer (mCRC) who may not benefit from first-line chemotherapy could guide the timely use of second-line treatments, potentially improving outcomes.
- The study analyzed the relationship between changes in carcinoembryonic antigen (CEA), circulating cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) during chemotherapy, finding that early ctDNA changes are more predictive of treatment response and survival outcomes than CEA.
- Results indicated that lack of a strong molecular response in ctDNA by the first evaluation was linked to shorter progression-free survival (PFS) and overall survival (OS), highlighting ctDNA's potential as a valuable biomarker in monitoring mCRC treatment.
Adsorption Behaviors of ctDNA and Biological Activities Based on Polyvinyl Alcohol/Polyethylene Glycol/Quaternized Chitosan Composite Hydrogel.
Molecules
December 2024
School of Stomatology and Optometry, Hubei University of Science and Technology, Xianning 437100, China.
Article Synopsis
- A ternary composite hydrogel made of PVA, PEG, and chitosan was created using electron-beam radiation and characterized using various analytical techniques.
- Systematic experiments showed that this hydrogel could adsorb up to 89% of calf thymus DNA, following a specific adsorption model and process.
- The bioactivity of the hydrogel was confirmed through tests for antibacterial activity and cytotoxicity, highlighting its potential in DNA adsorption and biomedical applications.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol
December 2024
Université de Paris Cité, Paris CARPEM Cancer Institute, Paris, France; INSERM UMR-S 1147, University of Paris Cité, Centre de Recherche des Cordeliers, Paris, France.
Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with advanced epithelial ovarian cancer (EOC) included in the CHIVA trial (NCT01583322).
Methods: Blood samples were collected at T0 and before each administration of NACT. Circulating tumor DNA detection was performed by next-generation sequencing.
Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.
Sci Rep
November 2024
Centre de Recherches en Cancérologie de Toulouse, CRCT, Toulouse University, CNRS, InsermToulouse, France.
In PDAC patients, ctDNA detection's prognostic significance needs validation especially in resected patients. This study investigated ctDNA kinetics in portal and peripheral blood before and after resection, and whether tissue mobilization during surgery influences ctDNA detection. In this single-center prospective cohort, portal and peripheral blood were drawn during pancreaticoduodenectomy before and after tissue mobilization, during 12 postoperative months and were associated with overall survival (OS), recurrence-free survival (RFS) and CA19-9 (secondary endpoints).
View Article and Find Full Text PDFRole of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.
J Exp Clin Cancer Res
September 2024
Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela, 15706, Spain.
Background: There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!